Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Rishi Singh
Study ID
NCT02559180
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • aflibercept — DRUG
    aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment

Study Details

Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)

Key Dates

Start date
Oct 31, 2015
Status verified
Mar 2023
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment

Primary Outcome Measure

Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline [ Time Frame: Baseline and 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cole Eye Institute, Cleveland ClinicClevelandOhio44195-

Find similar trials in Cleveland, OH

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
Cole Eye Institute, Cleveland Clinic· Cleveland, OH

Related Studies